Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 315,594,272
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 13,743 M
  • EBITDA $ 19,476 M
  • 60-Month Beta 0.35
  • Price/Sales 5.30
  • Price/Cash Flow 15.53
  • Price/Book 6.39

Options Overview Details

View History
  • Implied Volatility 30.27% (-0.43%)
  • Historical Volatility 23.82%
  • IV Percentile 85%
  • IV Rank 38.64%
  • IV High 47.30% on 04/08/25
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 14) 8.01 (3.93%)
  • Put/Call Vol Ratio 0.88
  • Today's Volume 1,023
  • Volume Avg (30-Day) 1,319
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 88,424
  • Open Int (30-Day) 84,833
  • Expected Range 195.48 to 211.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $2.53
  • Number of Estimates 6
  • High Estimate $2.77
  • Low Estimate $2.34
  • Prior Year $2.48
  • Growth Rate Est. (year over year) +2.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
182.39 +11.57%
on 03/24/26
204.34 -0.42%
on 04/02/26
-0.24 (-0.12%)
since 03/02/26
3-Month
178.08 +14.27%
on 01/21/26
212.71 -4.33%
on 02/18/26
+20.35 (+11.11%)
since 01/02/26
52-Week
122.48 +66.14%
on 04/09/25
212.71 -4.33%
on 02/18/26
+59.05 (+40.88%)
since 04/02/25

Most Recent Stories

More News
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Joshua Jackson is joined by Gritty to take the body check off the ice.

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 ...

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051

Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer patients...

AZN : 203.49 (+1.37%)
ZNTL : 2.63 (+2.33%)
MRK : 120.87 (+0.02%)
APRE : 0.7154 (+1.65%)
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three...

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
Forget the Endless AI Stock Debate: This Outperforming Sector is the One to Watch Now

Our top chart strategist explains what investors are missing amid all the chatter over software stocks and AI spending; plus, his favorite stock to trade right now.

AA : 71.53 (-0.74%)
GOOG : 294.46 (-0.15%)
GOOGL : 295.77 (-0.54%)
AZN : 203.49 (+1.37%)
INTC : 50.38 (+4.89%)
IGV : 80.34 (+0.71%)
^BTCUSD : 66,864.05 (+0.02%)
MWH : 29.72 (+0.27%)
Why Wedbush Thinks Norway Could Be Key for This Quantum Computing Stock -- and the Entire Industry

Norway's sovereign wealth fund invested $200 million in IonQ, $39 million in Rigetti, and $4 million in D-Wave. Wedbush sees this as a potential turning point for institutional investment in quantum computing...

MSFT : 373.46 (+1.11%)
GOOG : 294.46 (-0.15%)
GOOGL : 295.77 (-0.54%)
QBTS : 14.32 (+4.53%)
SKYT : 28.37 (+4.49%)
AZN : 203.49 (+1.37%)
IONQ : 29.30 (+5.43%)
RGTI : 14.19 (+5.11%)
AMZN : 209.77 (-0.38%)
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol...

AZN : 203.49 (+1.37%)
AZN.LN : 15,316.000 (+1.96%)
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

ZBH : 90.89 (-0.15%)
EW : 81.05 (-0.26%)
AZN : 203.49 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 210.59
2nd Resistance Point 207.46
1st Resistance Point 205.48
Last Price 203.49
1st Support Level 200.37
2nd Support Level 197.24
3rd Support Level 195.26

See More

52-Week High 212.71
Last Price 203.49
Fibonacci 61.8% 178.24
Fibonacci 50% 167.60
Fibonacci 38.2% 156.95
52-Week Low 122.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.